NVIDIA
NVDA
Tesla
TSLA
Super Micro Computer
SMCI
4
Palantir
PLTR
5
Applovin
APP
US Stock MarketDetailed Quotes
TGTX TG Therapeutics
- 29.340
- +0.130+0.45%
Close Feb 26 16:00 ET
- 29.100
- -0.240-0.82%
Post 20:01 ET
4.57BMarket Cap-293.40P/E (TTM)
29.955High29.000Low1.30MVolume29.280Open29.210Pre Close38.28MTurnover0.90%Turnover Ratio326.00P/E (Static)155.67MShares36.84052wk High23.78P/B4.25BFloat Cap12.93052wk Low--Dividend TTM144.91MShs Float149414.006Historical High--Div YieldTTM3.27%Amplitude0.956Historical Low29.449Avg Price1Lot Size
About TG Therapeutics Company
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Company Profile
SymbolTGTX
Company NameTG Therapeutics
Listing DateOct 7, 2005
Founded1993
CEOMr. Michael S. Weiss
MarketNASDAQ
Employees264
Fiscal Year Ends12-31
Address3020 Carrington Mill Boulevard,Suite 475
CityMorrisville
ProvinceNorth Carolina
CountryUnited States of America
Zip Code27560
Phone1-212-554-4484
Company Executives
- Name
- Position
- Salary
- Michael S. Weiss
- Chairman of the Board, Chief Executive Officer and President
- 15.84M
- Sean A. Power
- Chief Financial Officer, Treasurer and Corporate Secretary
- 1.87M
- Laurence N. Charney
- Lead Independent Director
- 304.70K
- Kenneth Hoberman
- Independent Director
- 264.70K
- Daniel Hume
- Independent Director
- 262.20K
- Dr. Yann Echelard
- Independent Director
- 262.20K
- Sagar Lonial, M.D.
- Independent Director
- 259.70K